Media headlines about CryoPort (NASDAQ:CYRX) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group rates the sentiment of media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. CryoPort earned a coverage optimism score of 0.09 on Accern’s scale. Accern also assigned media headlines about the consumer goods maker an impact score of 45.9414097321996 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the media headlines that may have effected Accern Sentiment Analysis’s scoring:
- Remarkable Runner -Cryoport, Inc. (CYRX) – Nasdaq Fortune (press release) (nasdaqfortune.com)
- CryoPort Inc (CYRX) Receives Average Rating of “Buy” from Brokerages (americanbankingnews.com)
- CryoPort Inc (CYRX) CEO Sells $287,596.31 in Stock (americanbankingnews.com)
- Cryoport, Inc. (CYRX) Reaches $9.58 After 9.00% Down Move; Spectrum Brands Holdings, Inc. (SPB) Had 13 Analysts … – MTA Star (mtastar.com)
Shares of CYRX stock traded down $0.16 during midday trading on Wednesday, reaching $10.03. 19,533 shares of the company’s stock were exchanged, compared to its average volume of 125,985. CryoPort has a 1 year low of $1.96 and a 1 year high of $10.40. The company has a market capitalization of $276.95, a PE ratio of -29.11 and a beta of 0.71.
CYRX has been the subject of several recent research reports. BidaskClub upgraded CryoPort from a “buy” rating to a “strong-buy” rating in a report on Wednesday. Needham & Company LLC reissued a “buy” rating and issued a $11.00 price objective (up from $10.00) on shares of CryoPort in a research report on Thursday, March 8th. Finally, Roth Capital began coverage on shares of CryoPort in a research report on Thursday, November 30th. They issued a “buy” rating and a $12.50 price objective for the company. One research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $33.70.
In related news, CEO Jerrell Shelton sold 29,257 shares of the firm’s stock in a transaction that occurred on Tuesday, March 13th. The shares were sold at an average price of $9.83, for a total transaction of $287,596.31. The transaction was disclosed in a document filed with the SEC, which is available at this link. 9.00% of the stock is owned by company insiders.
ILLEGAL ACTIVITY NOTICE: “CryoPort (NASDAQ:CYRX) Receiving Somewhat Favorable Media Coverage, Analysis Finds” was first reported by BBNS and is the property of of BBNS. If you are reading this piece of content on another domain, it was stolen and reposted in violation of US & international trademark & copyright laws. The correct version of this piece of content can be viewed at https://baseballnewssource.com/2018/03/21/cryoport-cyrx-earns-news-impact-score-of-0-09/2028905.html.
CryoPort Company Profile
Cryoport, Inc (Cryoport) is a provider of cryogenic logistics solutions to the life sciences industry through its purpose-built packaging, information technology and specialized cold chain logistics expertise. The Company provides logistics solutions for biologic materials, such as immunotherapies, stem cells, chimeric antigen receptors (CAR)-T cells, and reproductive cells for clients.
Receive News & Ratings for CryoPort Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort and related companies with MarketBeat.com's FREE daily email newsletter.